

Status: Currently Official on 16-Feb-2025  
 Official Date: Official as of 01-Aug-2017  
 Document Type: USP Monographs  
 DocId: GUID-BF5407E0-C675-4CFD-A3BB-21DB0C789397\_1\_en-US  
 DOI: [https://doi.org/10.31003/USPNF\\_M56131\\_01\\_01](https://doi.org/10.31003/USPNF_M56131_01_01)  
 DOI Ref: e1mnz

© 2025 USPC  
 Do not distribute

# Neomycin and Polymyxin B Sulfates, Bacitracin, and Hydrocortisone Acetate Ophthalmic Ointment

## DEFINITION

Neomycin and Polymyxin B Sulfates, Bacitracin, and Hydrocortisone Acetate Ophthalmic Ointment contains the equivalent of NLT 90.0% and NMT 140.0% of the labeled amounts of neomycin, polymyxin B, and bacitracin, and NLT 90.0% and NMT 110.0% of the labeled amount of hydrocortisone acetate in a suitable ointment base.

## IDENTIFICATION

- **A. THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST (201BNP):** Meets the requirements
- **B.** The retention time of the hydrocortisone acetate peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay for *Hydrocortisone Acetate*.

## ASSAY

### • NEOMYCIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment in a separator with 50 mL of [ether](#). Extract with four 20-mL portions of *Buffer B.3*. Combine the aqueous extracts, and dilute with *Buffer B.3* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.3* to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

**Acceptance criteria:** 90.0%–140.0%

### • POLYMYXIN B

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 25-mL portions of *Buffer B.6*. Combine the aqueous extracts, and dilute with *Buffer B.6* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with *Buffer B.6* to obtain a *Test Dilution* having a concentration that is nominally equivalent to the median level of the standard (10 polymyxin B units/mL). Add to each *Test Dilution* of the standard a quantity of [USP Neomycin Sulfate RS](#), dissolved in *Buffer B.6*, to obtain the same concentration of neomycin as in the *Test Dilution* of the sample.

**Acceptance criteria:** 90.0%–140.0%

### • BACITRACIN

(See [Antibiotics—Microbial Assays \(81\)](#).)

**Sample solution:** Shake a portion of Ophthalmic Ointment with 50 mL of [ether](#) in a separator. Extract with four 20-mL portions of *Buffer B.1*. Combine the buffer extracts, and dilute with *Buffer B.1* to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Add sufficient [0.01 N hydrochloric acid](#) to a portion of the *Sample solution* so that the amount of hydrochloric acid in the *Test Dilution* is the same as in the median level of the standard. Dilute with *Buffer B.1* to obtain a *Test Dilution* having a bacitracin concentration that is nominally equivalent to the median level of the standard.

**Acceptance criteria:** 90.0%–140.0%

### • HYDROCORTISONE ACETATE

**Mobile phase:** [Butyl chloride](#), water-saturated [butyl chloride](#), [tetrahydrofuran](#), [methanol](#), and [glacial acetic acid](#) (475:475:70:35:30)

**Standard solution:** 0.10 mg/mL of [USP Hydrocortisone Acetate RS](#) in water-saturated [chloroform](#)

**Sample solution:** Nominally 0.10 mg/mL of hydrocortisone acetate from Ophthalmic Ointment prepared as follows. Transfer a portion of Ophthalmic Ointment containing nominally 2.5 mg of hydrocortisone acetate to a closable container. Add 25.0 mL of water-saturated [chloroform](#) and about 10 glass beads. Securely close the container, and shake vigorously for approximately 15 min. Centrifuge, and use the clear, lower chloroform layer.

### Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 3.9-mm × 30-cm; 10-µm packing [L3](#)

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of hydrocortisone acetate (C<sub>23</sub>H<sub>32</sub>O<sub>6</sub>) in the portion of Ophthalmic Ointment taken:

Result = (r<sub>U</sub>/r<sub>S</sub>) × (C<sub>S</sub>/C<sub>U</sub>) × 100

- r<sub>U</sub> = peak response from the *Sample solution*
- r<sub>S</sub> = peak response from the *Standard solution*
- C<sub>S</sub> = concentration of [USP Hydrocortisone Acetate RS](#) in the *Standard solution* (mg/mL)
- C<sub>U</sub> = nominal concentration of hydrocortisone acetate in the *Sample solution* (mg/mL)

**Acceptance criteria:** 90.0%–110.0%

- SPECIFIC TESTS**
- **STERILITY TESTS** [\(71\)](#): Meets the requirements
  - **OTHER REQUIREMENTS:** It meets the requirements for *Particulate and Foreign Matter* and *Container Contents* in [Ophthalmic Products—Quality Tests \(771\)](#), [Drug Product Quality, Universal Tests, Particulate and Foreign Matter](#) and [Container Contents](#).

- ADDITIONAL REQUIREMENTS**
- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes.
  - **USP REFERENCE STANDARDS** [\(11\)](#):  
[USP Bacitracin Zinc RS](#)  
[USP Hydrocortisone Acetate RS](#)  
[USP Neomycin Sulfate RS](#)  
[USP Polymyxin B Sulfate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN, AND HYDROCORTISONE ACETATE OPHTHALMIC OINTMENT	<a href="#">Julie Zhang</a> Associate Science & Standards Liaison	BI042020 Biologics Monographs 4 - Antibiotics
REFERENCE STANDARD SUPPORT	RS Technical Services <a href="mailto:RSTECH@usp.org">RSTECH@usp.org</a>	BI042020 Biologics Monographs 4 - Antibiotics

**Chromatographic Database Information:** [Chromatographic Database](#)

**Most Recently Appeared In:**  
Pharmacopeial Forum: Volume No. PF 39(5)

**Current DocID:** GUID-BF5407E0-C675-4CFD-A3BB-21DB0C789397\_1\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M56131\\_01\\_01](https://doi.org/10.31003/USPNF_M56131_01_01)

**DOI ref:** [e1mnz](#)